SCHEMBL141004

SCHEMBL141004

C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3A Q14432 3/20 0.72
PDE4D Q08499 1/20 0.72
SLC29A1 Q99808 1/20 0.72
LMNA P02545 3/20 0.59
THRB P10828 1/20 0.59
MTOR P42345 1/20 0.59
MDM2 Q00987 1/20 0.59
NCOA1 Q15788 1/20 0.59
NCOA3 Q9Y6Q9 1/20 0.59
ADORA2A P29274 3/20 0.50
CACNA1F O60840 2/20 0.48
ALB P02768 2/20 0.48
MAPT P10636 2/20 0.48
CACNA1D Q01668 2/20 0.48
CACNA1S Q13698 2/20 0.48
CACNA1C Q13936 2/20 0.48
POLA1 P09884 1/20 0.48
ADA P00813 1/20 0.46
ADORA3 P0DMS8 2/20 0.40
ADORA2B P29275 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12621417 1.00 PDE3A (0.72) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL18561534 1.00 PDE3A (0.72) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL29325152 1.00 PDE3A (0.72) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL18537397 1.00 PDE3A (0.72) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL3159103 1.00 PDE3A (0.72) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL12151832 1.00 PDE3A (0.72) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL12149492 1.00 PDE3A (0.72) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL12150864 1.00 PDE3A (0.72) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL18561536 1.00 PDE3A (0.72) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL21006620 1.00 PDE3A (0.72) PDE3APDE4DSLC29A1LMNATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 839 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4566670-A2 MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS Gilead Sciences, Inc. (US) 2025-06-11 EP claimed
US-12083185-B2 Small polymeric carriers for delivery of agents University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2024-09-10 US claimed
EP-4403221-A2 MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS Gilead Sciences, Inc. (US) 2024-07-24 EP claimed
CN-118019981-A Methods for characterizing tumors 蒙彼利埃大学医疗中心 2024-05-10 CN claimed
CN-113054950-B Relaxation oscillator and memory chip 西安紫光国芯半导体有限公司 2023-11-21 CN claimed
CN-116726036-A Application of NM107 in resisting infectious pancreatic necrosis virus 中国水产科学研究院黑龙江水产研究所 2023-09-12 CN claimed
US-11021497-B2 Compositions and methods for synthesis of phosphorylated molecules THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-06-01 US claimed
US-20200385340-A1 HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS BIOTRON LTD (AU) 2020-12-10 US claimed
US-10793924-B2 Methods for detecting norovirus QUEST DIAGNOSTICS INVESTMENTS LLC (US) 2020-10-06 US claimed
US-20200239500-A1 Compositions and Methods for Synthesis of Phosphorylated Molecules THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-07-30 US claimed
US-20070161611-A1 POLYCYCLIC PHENOLIC COMPOUNDS AND USE IN TREATING VIRAL INFECTIONS MIGENIX CORPORATION 2007-07-12 US claimed
WO-2007062528-A1 POLYCYCLIC PHENOLIC COMPOUNDS AND USE IN TREATING VIRAL INFECTIONS MIGENIX CORPORATION (US) 2007-06-07 WO claimed
EP-1585529-A2 PROCESS FOR THE PRODUCTION OF 2'-BRANCHED NUCLEOSIDES Idenix (Cayman) Limited (KY) 2005-10-19 EP claimed
EP-1539188-A2 NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE Merck & Co., Inc. (US) 2005-06-15 EP claimed
US-20050020825-A1 Process for the production of 2'-branched nucleosides IDENIX PHARMACEUTICALS LLC 2005-01-27 US claimed
US-20040259934-A1 Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds OLSEN DAVID B (US) 2004-12-23 US claimed
WO-2004052899-A2 PROCESS FOR THE PRODUCTION OF 2'-BRANCHED NUCLEOSIDES IDENIX (CAYMAN) LIMITED (KY) 2004-06-24 WO claimed
US-20040110717-A1 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase MERCK SHARP & DOHME LLC 2004-06-10 US claimed
US-20040059104-A1 Nucleotide mimics and their prodrugs BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2004-03-25 US claimed
WO-2002057425-A2 NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE MERCK & CO., INC. (US) 2002-07-25 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200239500-A1 Compositions and Methods for Synthesis of Phosphorylated Molecules PIK3CA, CHAMP1, TYMP PDE3A 2076/4885PDE4D 1088/4885SLC29A1 498/4885
US-20040110717-A1 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase NSUN2, NSUN3, POLRMT PDE3A 1235/4885PDE4D 996/4885SLC29A1 118/4885
US-20040259934-A1 Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds SARS1, ACE, ACE2 PDE3A 1769/4885PDE4D 3152/4885SLC29A1 19/4885
US-12083185-B2 Small polymeric carriers for delivery of agents CD44, PGF, SLC46A1 PDE3A 2485/4885PDE4D 2909/4885SLC29A1 552/4885
US-11021497-B2 Compositions and methods for synthesis of phosphorylated molecules PIK3CA, CHAMP1, TYMP PDE3A 2076/4885PDE4D 1088/4885SLC29A1 498/4885
US-20070161611-A1 POLYCYCLIC PHENOLIC COMPOUNDS AND USE IN TREATING VIRAL INFECTIONS ACE, NCOA1, ACE2 PDE3A 4181/4885PDE4D 4462/4885SLC29A1 2181/4885
US-20040059104-A1 Nucleotide mimics and their prodrugs NUDT14, ENTPD5, MTAP PDE3A 765/4885PDE4D 212/4885SLC29A1 19/4885
US-20050020825-A1 Process for the production of 2'-branched nucleosides RNGTT, MTAP, NSUN2 PDE3A 1307/4885PDE4D 312/4885SLC29A1 152/4885
US-20200385340-A1 HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS HAVCR2, HCCS, EIF2AK2 PDE3A 602/4885PDE4D 2375/4885SLC29A1 2271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.